Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis다발성 경화증이 있는 혈청 음성인의 COVID-19 추가 백신 접종에 대한 반응Article Published on 2022-08-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] anti-CD20 therapy association benefit Blood blood sample booster booster vaccination Cellular immune response COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines demonstrated detectable Disease modifying therapies (DMTs) Evidence evidence of fingolimod humoral IgG IgG response immune response initial Laboratory Multiple multiple sclerosis Multiple sclerosis (MS) nucleocapsid antigen occurred participant Participants positive provided response SARS-CoV-2 spike protein Seroconversion seroconverted seronegative Spike protein T cell T cell response T-cell responses therapy treated vaccination Vaccine venous venous blood were measured Whole blood whole blood sample [DOI] 10.1016/j.msard.2022.103937 PMC 바로가기 [Article Type] Article
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination이종 및 동종 SARS-CoV-2 백신 접종에서 세포 및 체액성 면역 반응의 상호 의존성Observational Study Published on 2022-08-012022-09-11 Journal: Allergy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Anti-spike Antibody avidity association avidity blood sample Blood samples BNT162b2 booster booster vaccination cellular Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 group healthcare worker Heterologous homologous humoral Humoral and cellular immune responses humoral immune response humoral responses IgG levels immune immune response immune responses immunization interferon interferon-γ nCoV Neutralizing antibodies neutralizing antibody no significant differences Observational cohort study SARS-CoV-2 SARS-CoV-2 vaccination secondary immunization significant difference significant differences Spike protein T-cell T-cell activation T-cell Response T-cell responses unlikely vaccination [DOI] 10.1111/all.15247 PMC 바로가기 [Article Type] Observational Study
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatmentArticle Published on 2022-08-012022-10-05 Journal: ESMO open [Category] 진단, 치료법, [키워드] acute respiratory syndrome anti-spike antibody antibodies baseline BNT162b2 booster booster dose booster vaccination breakthrough infections Cancer cancer patient Cancer patients Care cause CD19+ CD4+ cell counts Cellular immune response cellular immunity cellular response Chemotherapy coronavirus COVID-19 COVID-19 infection died disease dose Efficacy Endocrine evaluated excluded exclusion criteria Factor Factors high risk high-risk population hospital humoral Humoral immunity immune response Immunosuppression immunosuppressive Infection Messenger RNA Mild mRNA mRNA vaccine mRNA-1273 mRNA-based neoplasm neutralizing antibody older patients Other outcome overcome Patient positive reduced required Result severe coronavirus disease significant increase significantly increased significantly lower solid malignancy solid tumors T-cell Response treated Treatment vaccination Vaccine vaccine dose Vaccines were assessed [DOI] 10.1016/j.esmoop.2022.100587 [Article Type] Article
Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccinationSARS-CoV-2 비활성화 백신 접종 후 장기간 회복 중인 COVID-19 개인의 강력한 체액 및 세포 면역 반응Article Published on 2022-08-012022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] addition anti-S Antigen antigen-specific T cell Antigen-specific T cells B cell booster caused CD4 Cellular immune response characterized convalescent COVID-19 death demonstrated Efficacy exhibited frequencies Frequency healthy healthy individual healthy individuals Hospitalization humoral IFN-γ IgG IL-2 immune immune responses inactivated Inactivated vaccine individual infected patient Infection long-term convalescent. NAbs Neutralizing antibodies neutralizing antibody neutralizing capacity RBD IgG RBD-specific IgG recipients recovered patient recovered patients robust SARS-CoV-2 SARS-CoV-2 inactivated vaccine SARS-CoV-2 RBD SARS-CoV-2 vaccine severe disease significantly significantly higher significantly increased single dose subject T cell T cell response T cell responses T cells the vaccine TNF-α utility vaccination Vaccine vaccine-induced immune response variants variants of concern VoC VOCs wild type [DOI] 10.3389/fimmu.2022.966098 PMC 바로가기 [Article Type] Article
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentResearch article Published on 2022-08-012022-10-05 Journal: Vaccine [Category] COVID19(2023년), SARS, 비임상, [키워드] adenoviral vector Adenovirus administration Antigen approved assessment benefit Benefit/Risk booster capillary leak syndrome cell line Cellular immune response ChAdOx1 circumvent clinical evaluation clinical trial collaboration conducted COVID-19 COVID-19 vaccination Deletion dose effective Emergency use authorization evaluate evaluated expressing Extensive feature fevers Genetic Guillain-barrè syndrome Hemorrhagic HIV humoral immune response Immune thrombocytopenia impair Influenza key consideration malaria manuscript MERS-CoV New Nipah virus Oxford-AstraZeneca platform pre-existing immunity Prophylactic Prostate cancer Replication reported risk Safety SARS-CoV-2 Serious Adverse Event serotype surveillance data syndrome therapeutic thrombosis Tuberculosis University of Oxford Vaccine Vaccine development Vaccines vectored vaccine virus Zika [DOI] 10.1016/j.vaccine.2022.06.008 [Article Type] Research article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study면역억제 환자에서 SARS-CoV-2 예방접종 및 추가 용량에 대한 세포 및 체액 면역 반응: 관찰 코호트 연구Observational Study Published on 2022-08-012022-09-12 Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Ad26.COV2.S anti-CD20 anti-SARS-CoV-2 S1 IgG B cell BNT162b2 booster booster dose booster vaccination Cellular immune response cellular immunity cellular response clinical COVID-19 defined ELISA Factor Healthcare system humoral humoral immune response IgG IGRA Immunosuppressed immunosuppressed patient Immunosuppression individual interferon gamma lymphoma median age monoclonal antibody mRNA-1273 Observational cohort study Patient patient groups performed populations positive receptor retrospective SARS-CoV-2 SARS-CoV-2 vaccination serology significantly higher sphingosine vaccination vaccine response variable were measured [DOI] 10.1016/j.jcv.2022.105217 PMC 바로가기 [Article Type] Observational Study
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts이종 및 동종 COVID-19 백신의 내구성 향상Article Published on 2022-08-012022-09-11 Journal: JAMA Network Open [Category] SARS, 변종, 진단, [키워드] Ad26 Ad26.COV2.S Adenovirus age Analysis Antibody Response Antibody responses Asian assays binding black BNT162b2 BNT162b2 vaccine boost Boston CD4+ T-cell CD8+ Cellular immune response cellular immune responses cohort study COVID-19 COVID-19 vaccine cytokine Data analysis declined elicited evaluate evaluated female Follow-up functional antibody response Heterologous heterologous prime-boost Hispanic homologous humoral humoral immune responses immune response immune responses immunization immunogenicity individual intracellular cytokine staining involved IQR Latino Massachusetts median Messenger RNA mRNA mRNA vaccine Neutralizing neutralizing antibodies titer neutralizing antibody occurred of BNT162b2 omicron outcome participant peaked potential benefit potential benefits prime-boost regimen rapid increase regimen repeated response SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants T-cell responses These data Vaccine was performed were assessed white [DOI] 10.1001/jamanetworkopen.2022.26335 PMC 바로가기 [Article Type] Article
Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody DeficiencyArticle Published on 2022-08-012022-11-15 Journal: Journal of Clinical Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] anti-S IgG antibody association Autoimmunity B-cells baseline CD19 CD4 CD8 Cellular immune response clinical Cohort common common variable immune deficiency coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 mRNA vaccines criteria CVID deficiency develop Diagnosis disease dose expression Frequency HCs humoral IgA IgG IgG deficiency IgG subclasse immune Immune profile immunological characteristics impairment investigated memory Moderna Moderna mRNA vaccine mRNA mRNA vaccine naïve neutralization activity OX40 Patient Pfizer-BioNTech Pfizer-BioNTech mRNA vaccine Poor predicted primary antibody primary antibody deficiency response responses SARS-CoV-2 spike protein Selective IgG subclass deficiency significantly lower Specific Specific antibody deficiency. subset T-cell T-cell Response T-cells vaccination Vaccine vaccine response [DOI] 10.1007/s10875-022-01296-4 PMC 바로가기
Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice스파이크 단백질을 발현하는 재조합 침팬지 아데노바이러스 벡터 백신은 생쥐에서 SARS-CoV-2 감염에 대해 효과적이고 지속적인 보호를 제공합니다Article Published on 2022-08-012022-09-11 Journal: Virologica Sinica [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Adenovirus Cellular immune response Chimpanzee Chimpanzee adenovirus vector clinical evaluation death dose dropped effective Effectiveness Efficacy expected expressing full-length global public health histological abnormalities histological abnormality histopathological examination humoral Humoral and cellular immune responses immune responses immunization immunized mice Infection Long-term protection lung Lungs mice Mild Neutralizing antibodies neutralizing antibody pandemic provide Rapid recombinant recombinant chimpanzee adenovirus SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic short term the SARS-CoV-2 the spike protein vaccination Vaccine variants of concern vectored vaccine Viral Viral load widespread [DOI] 10.1016/j.virs.2022.05.006 PMC 바로가기 [Article Type] Article